Sunrise Group Establishes U.S. Medical Advisory Board To Advance Sleep Care Innovation

Renowned Leaders In Sleep And Obesity Medicine Appointed To Sunrise’s U.S. Medical Advisory Board As The Company Achieves Nationwide Expansion

NEW YORK--(BUSINESS WIRE)--Sunrise Group, a pioneer in medical device innovation and sleep care, today announced its inaugural U.S. Medical Advisory Board. The first appointees are Dr. Atul Malhotra, Vice Chair of Medicine for Research and Research Chief of Pulmonary, Critical Care, and Sleep Medicine at the University of California, San Diego, and Dr. Diana Thiara, Associate Clinical Professor of Medicine at the University of California, San Francisco.

This advisory board will play a central role in shaping Sunrise’s clinical strategy, guiding product development, and supporting the continued evolution of new care pathways to improve access and outcomes for patients with sleep-related disorders.

“Establishing a medical advisory board with leading experts in sleep and obesity medicine is a pivotal step for us as we tackle the global sleep epidemic,” said Laurent Martinot, CEO and co-founder of Sunrise. “Among sleep-related disorders, sleep apnea remains the elephant in the room, and where the need is greatest. It remains wildly underdiagnosed, with more than 80% of cases going untreated. Even among those who are diagnosed, too many don’t receive the treatment and follow-up they need, leading to serious long-term consequences for individuals and massive impacts on public health. We’re excited to bring our advisors’ clinical and scientific expertise into our product roadmap and clinical approach, so we can continue advancing obstructive sleep apnea (OSA) diagnosis and support more accessible, scalable care pathways that better address the overlap between sleep health and obesity.”

Dr. Atul Malhotra is a board-certified pulmonologist, intensivist, and internationally recognized leader in sleep medicine. His expertise spans the diagnosis and treatment of sleep-related disorders, particularly sleep apnea, as well as narcolepsy, restless leg syndrome, and sleep disorders linked to medical or psychiatric conditions. He recently served as lead investigator on Eli Lilly’s SURMOUNT-OSA trial, which reported significant reductions in OSA severity with tirzepatide – a landmark study widely seen as a turning point in the field of sleep medicine.

"Sleep-related disorders have real health consequences when they go undiagnosed or left untreated,” said Dr. Atul Malhotra. “Combining advanced technology with rigorous, evidence-based research to expand access to reliable OSA diagnosis and high-quality sleep will help care for more patients.”

Dr. Diana Thiara is board-certified in internal medicine and is the medical director of the weight management program and program director of the obesity medicine fellowship at University of California, San Francisco. Her work sits at the intersection of clinical care, medical education, and program development for obesity care, with an emphasis on improving access to evidence-based treatment and helping shift the national dialogue on weight and health. Her clinical expertise and leadership in obesity medicine bring a critical perspective to Sunrise, particularly given the strong connection between obesity and OSA, and the opportunity to improve outcomes by addressing both together.

“With new GLP-1-based therapies, obesity care is at a historic inflection point,” said Dr. Diana Thiara. “Joining Sunrise’s Medical Advisory Board creates an unprecedented opportunity to address obesity and sleep apnea together, delivering coordinated, evidence-based care at exactly the time when science, innovation, and effective treatment options have aligned.”

Malhotra’s and Thiara’s appointments to Sunrise’s Medical Advisory Board strengthen the already deep clinical expertise of the company in sleep and obesity care, and reinforce its commitment to bringing scientifically rigorous care to more people, faster. This announcement follows Sunrise’s new funding of $29M, and comes as Sunrise’s digital sleep clinic, Dreem Health, expands nationwide in the United States, supporting the company’s goal of helping close persistent gaps in sleep care access.

About Sunrise Group

Founded in 2015, Sunrise Group® is a pioneer in medical device innovation and sleep care. The company first developed an FDA-cleared and CE-marked medical device – a lightweight, chin-worn sensor for at-home sleep apnea diagnosis using AI-supported analysis of mandibular jaw movements – that has been validated in peer-reviewed studies and endorsed by leading sleep experts. Today, Sunrise builds on that breakthrough to develop advanced software and hardware to detect, monitor, and treat sleep disorders, and brings this expertise to Dreem Health®, the U.S.-based virtual sleep clinic, available in all 50 states and covered by major insurers. Headquartered in Belgium with offices in France and the United States, the team brings together leaders in sleep research, patient care, and medical technology. To learn more about Sunrise and Dreem Health, visit us.hellosunrise.com and dreemhealth.com.